Evidence map›Paper›PMID 24917597›Full record

ArticlemBio2014

The ADP-ribosyltransferase domain of the effector protein ExoS inhibits phagocytosis of Pseudomonas aeruginosa during pneumonia.

Stephanie M Rangel, Latania K Logan, Alan R Hauser

Open access · goldAbstract read
In one paragraph

Article in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Targeting biofilm and virulence inMicrobiology spectrum · 2026
    Article
  4. Article
  5. Biofilm Formation ofMicroorganisms · 2025
    Review
  6. Article
  7. Article
  8. Evidence for intracellularJournal of bacteriology · 2024
    Review
  9. Anti-Microorganisms · 2023
    Review
  10. Frontiers in oncology · 2022
    Review
  11. Modulation of the immune response by theFrontiers in cellular and infection microbiology · 2022
    Review
  12. Genomic and Metabolic Characteristics of the Pathogenicity inInternational journal of molecular sciences · 2021
    Review
  13. CRISPR Element Patterns vs. Pathoadaptability of ClinicalAntibiotics (Basel, Switzerland) · 2021
    Article
  14. Review
  15. International journal of molecular sciences · 2021
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Effects of human β-defensin 3 fused with carbohydrate-binding domain on the function of type III secretion system in Pseudomonas aeruginosa PA14.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Stephanie M RangelDepartment of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Latania K LoganDepartment of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Alan R Hauserahauser@northwestern.edu.
Northwestern University · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
Mechanistic Studies of Patatin-like ToxinsR01AI053674 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2003 to 2017
$4.3M
Validating targets in p. aeruginosa type III secretion using chemical probesR01AI099269 · NIAID · MICROBIOTIX, INC · PI MOIR, DONALD T · 2012 to 2015
$3.2M
Type III Secretion Inhibitors for Anti-Infective TherapyR44AI068185 · NIAID · MICROBIOTIX, INC · PI MOIR, DONALD T · 2011 to 2013
$3.0M
Pseudomonas aeruginosa Genomic Islands and VirulenceR01AI075191 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2009 to 2013
$1.7M
Patient-Oriented Research on Pseudomonas aeruginosaK24AI104831 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2013 to 2024
$1.2M
Mechanism of Azithromycin Activity in Pseudomonas InfectionsR21AI088286 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2010 to 2011
$438k
The role of Pseudomonas aeruginosa ExoS during early pneumonia.F31AI089015 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI RANGEL, STEPHANIE M · 2010 to 2014
$136k
NCI NIH HHS CA060553NCI NIH HHS P30 CA060553NIAID NIH HHS AI04831NIAID NIH HHS AI053674NIAID NIH HHS AI075191NIAID NIH HHS AI088286NIAID NIH HHS AI089015NIAID NIH HHS AI099269NIAID NIH HHS F31 AI089015NIAID NIH HHS K24 AI104831NIAID NIH HHS R01 AI053674NIAID NIH HHS R01 AI075191NIAID NIH HHS R01 AI099269NIAID NIH HHS R21 AI088286NIAID NIH HHS R44 AI068185
6 · The paper itself

Abstract

unlabelledPseudomonas aeruginosa is a Gram-negative pathogen commonly associated with nosocomial infections such as hospital-acquired pneumonia. It uses a type III secretion system to deliver effector proteins directly into the cytosol of host cells. Type III secretion in P. aeruginosa has been linked to severe disease and worse clinical outcomes in animal and human studies. The majority of P. aeruginosa strains secrete ExoS, a bifunctional toxin with GTPase-activating protein and ADP-ribosyltransferase activities. Numerous in vitro studies have investigated the targets and cellular effects of ExoS, linking both its enzymatic activities with inhibition of bacterial internalization. However, little is known about how this toxin facilitates the progression of infection in vivo. In this study, we used a mouse model to investigate the role of ExoS in inhibiting phagocytosis during pneumonia. We first confirmed previous findings that the ADP-ribosyltransferase activity of ExoS, but not the GTPase-activating protein activity, was responsible for bacterial persistence and decreased host survival in this model. We then used two distinct assays to demonstrate that ExoS inhibited phagocytosis during pneumonia. In contrast to the findings of several in vitro studies, this in vivo inhibition was also dependent on the ADP-ribosyltransferase activity, but not the GTPase-activating protein activity, of ExoS. These results demonstrate for the first time the antiphagocytic function of ExoS in the context of an actual infection and indicate that blocking the ADP-ribosyltransferase activity of ExoS may have potential therapeutic benefit. IMPORTANCE: Pseudomonas aeruginosa is a major cause of hospital-acquired infections. To cause severe disease, this bacterium uses a type III secretion system that delivers four effector proteins, ExoS, ExoT, ExoU, and ExoY, into host cells. The majority of P. aeruginosa strains secrete ExoS, a bifunctional toxin with GTPase-activating protein and ADP-ribosyltransferase activities. In cell culture models, both enzymatic activities have been associated with decreased bacterial internalization. However, our study is the first to examine a role for ExoS in blocking phagocytosis in an animal model. We report that ExoS does inhibit phagocytosis during pneumonia. The ADP-ribosyltransferase activity, but not the GTPase-activating protein activity, of ExoS is necessary for this effect. Our findings highlight the ability of P. aeruginosa to manipulate the inflammatory response during pneumonia to facilitate bacterial survival.

Indexed as

PhagocytosisADP Ribose TransferasesAnimalsBacterial ProteinsBacterial ToxinsFemaleHumansMiceMice, Inbred BALB CPneumoniaProtein Structure, TertiaryPseudomonas aeruginosaPseudomonas InfectionsADP Ribose TransferasesBacterial ProteinsBacterial Toxinsexoenzyme S

Identifiers

PMID24917597
PMCPMC4056551
OpenAlexW2152197904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.